ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis

Song, Yaowen; Lin, Shuiyu; Chen, Jun; Dang, Jun*哈尔滨医科大学; 中国医科大学; 1
BMC CANCER2023-10-30DOI: 10.1186/s12885-023-11548-0
1被引14阅读
引用收藏
分享

摘要

Background It remains uncertain whether first-line treatment with upfront brain radiotherapy (RT) in combined with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is superior to EGFR-TKIs alone for EGFR-mutated non-small cell lung cancer with newly diagnosed brain metastases (BMs). Therefore, we performed a meta-analysis to address this issue.Methods We searched PubMed, Embase, Cochrane Library, and Web of Science databases for eligible studies published until February 28, 2023. The primary outcomes of interest were overall survival (OS) and intracranial progression-free survival (iPFS), reported as hazard ratios (HRs) and 95% confidence intervals (CIs).Results Twenty-four retrospective studies with 3184 patients were included. First- or second-generation EGFR-TKIs were used in each study. Upfront brain RT plus EGFR-TKIs significantly prolonged OS (HR = 0.75, 95% CI: 0.64-0.88) and iPFS (HR = 0.61, 95% CI: 0.52-0.72) compared to EGFR-TKIs alone. There were no significant differences in OS and iPFS benefits from the combination therapy between asymptomatic and symptomatic patients, patients with exon 19 and 21 mutations, patients with 1-3 and > 3 BMs, and males and females, respectively (HRs interaction, P > 0.05 for each subgroup comparison).Conclusions First-line treatment with upfront brain RT plus EGFR-TKIs is likely to be more effective than EGFR-TKIs alone. The benefits of combination therapy did not appear to be significantly affected by BM-related symptoms, EGFR mutation subtype, number of BMs, or sex.

学科与关键词

关键词
Non-small-cell Lung cancerBrain metastasesEpidermal growth factor receptor tyrosine kinase inhibitorsBrain radiotherapymeta-analysis
相关
加载中…
  • Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study
    Hou, Xue; Li, Meichen; Wu, Guowu; Feng, Weineng; Su, Jin; Jiang, Honghua; Jiang, Guanming; Chen, Jing; Zhang, Baishen; You, Zhixuan; Liu, Qing; Chen, Likun*JAMA Network Open, 2023, 6(2): e2255050.被引 4
  • EGFR抑制剂治疗EGFR突变型晚期非小细胞肺癌的Meta分析
    张蓉; 陈薇雅; 甘洁民; 赵虎; 顾兆祥检验医学, 2013, (06): 506.
  • Clinical outcomes of EGFR plus /METamp plus vs. EGFR plus /METamp- untreated patients with advanced non-small cell lung cancer
    Peng, Kai-Cheng; Su, Jun-Wei; Xie, Zhi; Wang, Han-Min; Fang, Mei-Mei; Li, Wen-Feng; Chen, Yu-Qing; Guan, Xu-Hui; Su, Jian; Yan, Hong-Hong; Zhang, Xu-Chao; Tu, Hai-Yan; Zhou, Qing; Chen, Hua-Jun; Wu, Yi-Long; Yang, Jin-Ji*Thoracic Cancer, 2022, 13(11): 1619-1630.被引 5
查看全部 →

发表信息

论文状态
公开发表
期刊
BMC CANCER
发表日期
2023-10-30
卷期
第 23 卷, 第 1 期
页码
1043
DOI
10.1186/s12885-023-11548-0
语言
ENGLISH
成果收录
SCIE
资助标注
Not applicable.

作者

  • S

    Song, Yaowen (第一作者)

    1 · china med univ

  • L

    Lin, Shuiyu

    harbin med univ

查看全部 4 位作者收起作者
  • C

    Chen, Jun

  • D

    Dang, Jun (通讯)

    1 · china med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417